Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901099 | 0.85 | NPC1 (0.47) | KMT2ARIPK1ANPEPNPC1RAB9A | |
| SCHEMBL4901844 | 0.82 | PPIA (0.55) | KMT2ARIPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL4904332 | 0.82 | KMT2A (0.46) | KMT2AANPEPNPC1RAB9AALDH1A1 | |
| SCHEMBL4900916 | 0.81 | ALDH1A1 (0.55) | KMT2ANPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4892285 | 0.81 | NPC1 (0.49) | KMT2ANPC1RAB9AMAPTCASR | |
| SCHEMBL5444745 | 0.79 | KMT2A (0.51) | KMT2ARIPK1ANPEPNPC1RAB9A | |
| SCHEMBL4901901 | 0.78 | EPHX2 (0.52) | NPC1RAB9AP2RX7EPHX2 | |
| SCHEMBL14088790 | 0.76 | EPHX1 (0.71) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL2456852 | 0.75 | KMT2A (0.58) | KMT2ARIPK1ANPEPNPC1RAB9A | |
| SCHEMBL28559896 | 0.75 | KMT2A (0.63) | KMT2ARIPK1ANPEPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2C, ADRA2A | KMT2A 1150/4885RIPK1 4878/4885ANPEP 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.